Drug treatment for HF was well established, with 550 (90.2%), 561 (92.0%), 444 (72.8%), and 60 (9.8%) patients receiving medical therapy with renin angiotensin system inhibitors (RASi), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), and sodium-glucose co-transporter−2 inhibitors (SGLT2i), respectively. Here, NR3C2 is linked to hydrops fetalis.